Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)

NCT03849469 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.

NCT NCT03849469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03849469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Lead sponsor
Xencor, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 29, 2019
Completion date
February 16, 2023
Enrollment
78 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, cervical carcinoma, colorectal carcinoma, endometrial carcinoma, epithelial ovarian cancer, fallopian tube cancer, gastric or gastroesophageal junction adenocarcinoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, melanoma, nasopharyngeal carcinoma, non-small cell lung carcinoma, pancreatic carcinoma, primary peritoneal carcinoma, prostate carcinoma, renal cell carcinoma, small cell lung carcinoma, squamous cell anal cancer, squamous cell carcinoma of the head and neck, squamous cell penile carcinoma, squamous cell vulvar carcinoma, triple negative breast cancer, urothelial carcinoma